AR073511A1 - Derivados de isoquinolinona como antagonistas de nk3 - Google Patents

Derivados de isoquinolinona como antagonistas de nk3

Info

Publication number
AR073511A1
AR073511A1 ARP090103522A ARP090103522A AR073511A1 AR 073511 A1 AR073511 A1 AR 073511A1 AR P090103522 A ARP090103522 A AR P090103522A AR P090103522 A ARP090103522 A AR P090103522A AR 073511 A1 AR073511 A1 AR 073511A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkynyl
alkenyl
ring atoms
halogen
Prior art date
Application number
ARP090103522A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41227186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073511(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR073511A1 publication Critical patent/AR073511A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a compuestos para el tratamiento de la psicosis, a composiciones que comprenden dichos compuestos, y a métodos para tratar enfermedades que comprenden la administracion de dichos compuestos. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) en donde A representa N, CH o CR1, cada R1 representa independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -C(O)-alquilo C1-6, -C(O)-alquenilo C2-6, -C(O)-alquinilo C2-6, -C(O)-O-alquilo C1-6, -C(O)-O-alquenilo C2-6, -C(O)-O-alquinilo C2-6 o fenilo, en donde dicho fenilo, alquilo C1-6, alquenilo C2-6, o alquinilo C2-6 está opcionalmente sustituido con uno o varios sustituyentes seleccionados de halogeno, hidroxilo, haloalquilo C1-6, nitro, alcoxi C1- 6 y NR2R3; X representa hidrogeno, alquilo C1-6, opcionalmente sustituido con F, o -CRaRb-X', en donde X' representa un resto monocíclico saturado que tiene 5-6 átomos anulares, uno de los cuales es N, y en donde uno o dos átomos anulares adicionales pueden ser un heteroátomo seleccionado de N, O y S, donde el anillo monocícIico puede estar sustituido con uno o varios sustituyentes W, en donde W se selecciona de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6 o (=O); Ra y Rb, cada uno individualmente, representa hidrogeno, -CH3 o halogeno; Q representa un enlace, -CH2-, -NH- o -O-; Y representa alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, en donde dicho alquilo, alquenilo o alquinilo puede estar sustituido con uno o varios sustituyentes P, en donde P se selecciona de halogeno, hidroxi, alcoxi C1-6, ciano, -S-alquilo C1-6 y un resto monocíclico saturado que tiene 5-6 átomos anulares, en donde uno de los átomos anulares puede ser N y el resto es C; o Y puede representar un resto monocíclico saturado que tiene 4-6 átomos anulares, en donde uno de dichos átomos anulares se puede seleccionar de N y O, siendo el resto C, y donde dicho resto saturado monocíclico puede estar sustituido con uno o varios sustituyentes Z, en donde Z se selecciona de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, (=O), -C(O)H, -C(O)-alquilo C1-6, halogeno, alcoxi C1-6, hidroxialquilo C1-6 e hidroxi; en donde cada uno de R2 y R3 representa independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxialquilo C1-6 o haloalquilo C1-6; cada uno de R4-R8 y R9-R12 representa independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, NR2R3, hidroxi, ciano, nitro, alcoxi C1-6, haloalquilo C1-6 o hidroxialquilo C1-6; con la condicion de que dicho compuesto sea diferente de (1-fenil-etil)-amida del ácido 2-metil-1-oxo-1,2-dihidro-isoquinolin-4-carboxílico; y sales farmacéuticamente aceptables de dichos compuestos.
ARP090103522A 2008-09-15 2009-09-14 Derivados de isoquinolinona como antagonistas de nk3 AR073511A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200801290 2008-09-15
DKPA200900010 2009-01-06

Publications (1)

Publication Number Publication Date
AR073511A1 true AR073511A1 (es) 2010-11-10

Family

ID=41227186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103522A AR073511A1 (es) 2008-09-15 2009-09-14 Derivados de isoquinolinona como antagonistas de nk3

Country Status (27)

Country Link
EP (1) EP2342182B1 (es)
JP (1) JP5536776B2 (es)
KR (1) KR101638641B1 (es)
CN (1) CN102149685B (es)
AR (1) AR073511A1 (es)
AU (1) AU2009291309B2 (es)
BR (1) BRPI0917245B8 (es)
CA (1) CA2732612C (es)
CL (1) CL2011000533A1 (es)
CO (1) CO6351781A2 (es)
CY (1) CY1113743T1 (es)
DK (1) DK2342182T3 (es)
EA (1) EA021581B1 (es)
ES (1) ES2399177T3 (es)
HR (1) HRP20130038T1 (es)
IL (1) IL210236A (es)
MX (1) MX2011001786A (es)
MY (1) MY164998A (es)
NZ (1) NZ591265A (es)
PL (1) PL2342182T3 (es)
PT (1) PT2342182E (es)
RS (1) RS52674B (es)
SI (1) SI2342182T1 (es)
SM (1) SMT201300020B (es)
TW (1) TWI454461B (es)
WO (1) WO2010028655A1 (es)
ZA (1) ZA201103119B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
TW201000458A (en) 2008-06-23 2010-01-01 Lundbeck & Co As H Isoquinolinone derivatives as NK3 antagonists
WO2010045948A1 (en) 2008-10-20 2010-04-29 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
MX2014005705A (es) * 2011-11-09 2014-09-04 Abbvie Deutschland Carboxamidas heterociclicas utiles como inhibidores de fosfodiesterasa del tipo 10a.
SG11202010583VA (en) * 2018-04-27 2020-11-27 Sojournix Inc Polymorphic and amorphous forms of isoquinolinone and methods of use thereof
WO2023152888A1 (ja) * 2022-02-10 2023-08-17 カルナバイオサイエンス株式会社 フルオロイソキノリン化合物およびその製造法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
DE60208178T2 (de) * 2001-04-11 2006-08-24 Glaxosmithkline S.P.A. Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists

Also Published As

Publication number Publication date
WO2010028655A1 (en) 2010-03-18
NZ591265A (en) 2013-02-22
SMT201300020B (it) 2013-05-06
IL210236A0 (en) 2011-03-31
ZA201103119B (en) 2012-09-26
BRPI0917245A2 (pt) 2015-11-10
TW201010979A (en) 2010-03-16
RS52674B (en) 2013-06-28
MY164998A (en) 2018-02-28
JP5536776B2 (ja) 2014-07-02
ES2399177T3 (es) 2013-03-26
CA2732612C (en) 2016-08-09
BRPI0917245B8 (pt) 2021-05-25
SI2342182T1 (sl) 2013-04-30
CA2732612A1 (en) 2010-03-18
IL210236A (en) 2013-08-29
MX2011001786A (es) 2011-03-29
EP2342182A1 (en) 2011-07-13
EA021581B1 (ru) 2015-07-30
CO6351781A2 (es) 2011-12-20
HRP20130038T1 (hr) 2013-02-28
CN102149685B (zh) 2015-01-07
AU2009291309A1 (en) 2010-03-18
KR101638641B1 (ko) 2016-07-11
CL2011000533A1 (es) 2011-08-26
BRPI0917245B1 (pt) 2020-07-28
AU2009291309B2 (en) 2014-07-17
EP2342182B1 (en) 2012-11-14
JP2012502069A (ja) 2012-01-26
CY1113743T1 (el) 2016-06-22
DK2342182T3 (da) 2013-02-04
BRPI0917245A8 (pt) 2018-08-14
PL2342182T3 (pl) 2013-04-30
KR20110059849A (ko) 2011-06-07
TWI454461B (zh) 2014-10-01
PT2342182E (pt) 2013-02-11
CN102149685A (zh) 2011-08-10
EA201170447A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
AR073511A1 (es) Derivados de isoquinolinona como antagonistas de nk3
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
AR072198A1 (es) Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR070221A1 (es) Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR073891A1 (es) Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.
AR078786A1 (es) Derivados de la cromenona
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
CO6420337A2 (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
AR079497A1 (es) Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a
ECSP088257A (es) Derivados de amida
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek

Legal Events

Date Code Title Description
FG Grant, registration